HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target

Di Mao, Zheng Yuan, Fenfen Xu, Xiao Han, Hongyang ZhaoFrontiers in Neurology 2022 · DOI

TL;DR

This review identifies High-mobility group box-1 (HMGB1) as a "master alarmin" that drives neuroinflammation across a surprisingly broad spectrum of neurological disorders, from Parkinson’s and stroke to autism and depression. By synthesizing preclinical and clinical data, the authors argue that HMGB1 is not just a common thread in CNS pathology but a high-priority target for both diagnostic biomarkers and novel "release-inhibiting" therapies.

What Problem Does This Paper Address?

Neuroinflammation is a double-edged sword: while necessary for repair, its chronic activation is a primary driver of neuronal death in most nervous system diseases. However, finding a "universal" molecular trigger that can be targeted across different conditions has been difficult.

This paper addresses the role of HMGB1, a protein that normally lives in the nucleus helping to package DNA. When cells are stressed, damaged, or dying, HMGB1 is translocated to the cytoplasm and secreted into the extracellular space. Once outside, it acts as a potent pro-inflammatory signal. The authors tackle the challenge of consolidating disparate research to show how this single protein mediates damage in conditions as diverse as acute trauma (TBI, stroke), chronic degeneration (ALS, Parkinson’s), and psychiatric/developmental disorders (depression, autism).

Methods

As a comprehensive review, this paper does not introduce a new laboratory technique but rather performs a meta-synthesis of existing literature. The authors categorize research into two main streams:

  1. Mechanistic Studies: Mapping how HMGB1 interacts with receptors like RAGE (Receptor for Advanced Glycation End-products) and TLR4 (Toll-like Receptor 4) to trigger the NF-κB and MAP kinase pathways.
  2. Interventional Studies: Evaluating the efficacy of HMGB1 antagonists in animal models. These include:
  3. Neutralizing agents: Anti-HMGB1 monoclonal antibodies (mAbs) and the HMGB1 A-box (a competitive antagonist).
  4. Release inhibitors: Small molecules like Glycyrrhizin (GL) (derived from licorice) and Ethyl Pyruvate (EP) that prevent the protein from leaving the cell.

Datasets

The paper synthesizes data from a wide array of established experimental models and clinical cohorts, including:

  • Animal Models: MPTP and 6-OHDA (Parkinson’s), MCAO (Stroke), CCI (Traumatic Brain Injury), Pilocarpine-induced epilepsy, and SOD1G93A transgenic mice (ALS).
  • Clinical Data: Postmortem brain tissue, cerebrospinal fluid (CSF), and serum samples from patients with Parkinson’s, TBI, Autism Spectrum Disorder (ASD), and Multiple Sclerosis (MS).

Key Insights and Ideas

  • The "Alarmin" Mechanism: HMGB1 is unique because it is released both passively (leaking out of dead/necrotic cells) and actively (secreted by stressed neurons and microglia). This creates a "vicious cycle" where inflammation causes cell death, which releases more HMGB1, further fueling inflammation.
  • Redox Sensitivity: The protein’s function changes based on its oxidation state. "Disulfide HMGB1" is the primary pro-inflammatory culprit, while "fully oxidized HMGB1" is generally inert. This nuance is critical for developing specific drugs.
  • Blood-Brain Barrier (BBB) Integrity: A recurring finding across stroke and TBI studies is that HMGB1 directly contributes to the breakdown of the BBB. Inhibiting HMGB1 has been shown to preserve barrier function and reduce brain edema.
  • The Gut-Brain Axis in Autism: Interestingly, the paper highlights that elevated HMGB1 in children with autism correlates not only with symptom severity but also with gastrointestinal dysfunction, suggesting a systemic inflammatory component to the disorder.

Key Results

  • Parkinson’s Disease: In mouse models, anti-HMGB1 antibodies significantly inhibited microglial activation and reduced the loss of dopaminergic neurons in the substantia nigra.
  • Stroke: Clinical meta-analyses show a direct correlation between high serum HMGB1 levels and larger infarct volumes (size of the brain injury).
  • Traumatic Brain Injury: HMGB1 levels in plasma were found to be a significant predictor of 1-year survival in TBI patients.
  • Depression: Preclinical studies using "chronic unpredictable mild stress" models showed that inhibiting HMGB1 translocation in the hippocampus could eliminate depression-like behaviors in rodents.

Limitations and Future Work

Despite the promising data, the authors note several hurdles for clinical translation:

  • Clinical Lag: Most successful interventions (like anti-HMGB1 mAbs) are currently limited to animal models; human clinical trials are sparse.
  • Diagnostic Specificity: Because HMGB1 is elevated in so many different diseases, it may serve better as a marker of disease severity or progression rather than a specific diagnostic tool for a single condition.
  • Safety Concerns: HMGB1 has essential functions inside the nucleus (DNA repair). Long-term systemic inhibition could potentially interfere with normal cellular maintenance or lead to autoimmunity.
  • Isoform Detection: Current clinical tests (like standard ELISA) struggle to distinguish between the different redox isoforms of HMGB1, which is necessary to identify the "harmful" version of the protein accurately.

Summary updated

Abstract

High-mobility group box-1 (HMGB1) is a nuclear protein associated with early inflammatory changes upon extracellular secretion expressed in various cells, including neurons and microglia. With the progress of research, neuroinflammation is believed to be involved in the pathogenesis of neurological diseases such as Parkinson's, epilepsy, and autism. As a key promoter of neuroinflammation, HMGB1 is thought to be involved in the pathogenesis of Parkinson's disease, stroke, traumatic brain injury, epilepsy, autism, depression, multiple sclerosis, and amyotrophic lateral sclerosis. However, in the clinic, HMGB1 has not been described as a biomarker for the above-mentioned diseases. However, the current preclinical research results show that HMGB1 antagonists have positive significance in the treatment of Parkinson's disease, stroke, traumatic brain injury, epilepsy, and other diseases. This review discusses the possible mechanisms by which HMGB1 mediates Parkinson's disease, stroke, traumatic brain injury, epilepsy, autism, depression, multiple sclerosis, amyotrophic lateral sclerosis, and the potential of HMGB1 as a biomarker for these diseases. Future research needs to further explore the underlying molecular mechanisms and clinical translation.
BibTeX
@inproceedings{mao2022hmgb,
  author = {Di Mao and Zheng Yuan and Fenfen Xu and Xiao Han and Hongyang Zhao},
  title = {{HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target}},
  booktitle = {Frontiers in Neurology},
  year = {2022},
  doi = {10.3389/fneur.2022.1029891},
}
Figure